Table 2.

The Association of Co-expression of LGR5, CD133 status, and Clinicopathological Outcome of Gastric Cancer

Clinicopathological Outcome	LGR5 and CD 133 Status (n = 400)		OR (95% CI)	P
−/− or +/−, −/+ (n = 217)	+/+ (n = 183)
Location of tumor [n (%)]
Upper	28 (12.90)	32 (17.48)	0.75 (0.53-0.87)	.519
Middle	57 (26.27)	45 (24.59)	0.66 (0.41-0.84)	.622
Lower	132 (60.83)	106 (57.92)	0.74 (0.52-0.91)	.537
Tumor size
<70 mm	162 (74.65)	144 (78.68)	0.64 (0.41-0.82)	.475
≥70 mm	55 (25.35)	39 (21.31)	0.71 (0.51-0 .93)	.714
Histologic type
Differentiated	169 (77.88)	128 (69.95)	0.84 (0.61-0.98)	.692
Undifferentiated	48 (22.12)	55 (30.05)	0.62 (0.49-0.94)	.764
Lymphatic invasion
Absent	194 (89.40)	69 (37.70)	0.29 (0.16-0.88)	.026*
Present	23 (10.60)	114 (62.30)	5.83 (2.28-8.74)	.015*
Vascular invasion
Absent	184 (84.80)	74 (40.44)	0.17 (0.18-0.64)	.039*
Present	33 (15.20)	109 (59.56)	3.24 (1.54-6.92)	.025*
Pathological T stage
T1-T2	174 (80.18)	31 (16.94)	5.85 (2.41-8.77)	.017*
T3-T4	43 (19.82)	152 (83.06)	4.72 (2.27-7.14)	.028*
Pathological TNM stage
I	34 (15.67)	16 (8.74)	0.95 (0.62-1.17)	.198
II	67 (30.88)	29 (15.85)	0.82 (0.51-1.04)	.136
III	78 (35.94)	58 (31.70)	0.62 (0.41-0.87)	.627
IV	38 (17.51)	82 (44.81)	2.36 (0.51-0.97)	.035*

Univariate logistic regression model analysis. *P < .05 is considered statistically significant.